4 assets in Embryonal Rhabdomyosarcoma

Therapeutic assets addressing Embryonal Rhabdomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Embryonal Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Dactinomycin Embryonal Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vincristine Sulfate Embryonal Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vinorelbine Ditartrate Embryonal Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)